| Objective: To evaluate the efficacy and safety of ceftriaxone in the treatment of neurosyphilis,thus providing clinical evidence for the effective therapeutic solution to neurosyphilis.Methods: Starting from the establishment of computer retrieval database to March 1,2021,Pub Med,EMBASE,Cochrane Library,the web of science,clinical trials,CNKI,Wanfang database,CBM were included in the RCT of ceftriaxone for the treatment of neurosyphilis.The system evaluation method designed for the international Cochrane collaborative network was applied to carry out systematic evaluation.Two researchers were deployed to extract data and conduct quality assessment independently.Then,Revman 5.3 software was used to carry out system analysis.Results: There were four RCTs involving 162 neurosyphilis patients included.In contrast to penicillin,ceftriaxone exhibited no significant variation in efficacy after 6months(RR: 1.12,95%CI: 0.66-1.89),12 months(RR: 1.06,95%CI: 0.85-1.33)and 18months(RR: 0.97,95%CI: 0.86-1.10)(P>0.05).Besides,there was no significant difference observed between ceftriaxone and penicillin preparation(RR: 0.89,95%CI:0.76～1.05,P=0.18>0.05).Morover,there was no report on the serious systemic adverse reactions caused by ceftriaxone and penicillin.Conclusion: The efficacy and safety of ceftriaxone in the treatment of neurosyphilis are comparable to that of penicillin control group.In spite of this,it remains necessary to confirm how dosage relates to efficacy and safety with more RCTs. |
PDF Full Text Request